New York State Teachers Retirement System Cuts Stake in Medpace Holdings, Inc. $MEDP

New York State Teachers Retirement System decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,703 shares of the company’s stock after selling 1,009 shares during the quarter. New York State Teachers Retirement System owned 0.10% of Medpace worth $13,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its holdings in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the period. Franklin Resources Inc. grew its holdings in shares of Medpace by 158.6% during the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after buying an additional 183,645 shares in the last quarter. Norges Bank acquired a new position in shares of Medpace in the 4th quarter valued at about $102,156,000. Finally, Goldman Sachs Group Inc. boosted its position in Medpace by 92.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after purchasing an additional 166,654 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MEDP has been the subject of several recent research reports. Royal Bank Of Canada dropped their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Barclays cut their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Weiss Ratings cut Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Finally, BMO Capital Markets cut their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $467.08.

Medpace Price Performance

Shares of MEDP opened at $557.60 on Monday. The firm has a market capitalization of $15.93 billion, a P/E ratio of 35.05, a PEG ratio of 2.83 and a beta of 1.15. The business has a fifty day moving average of $453.88 and a 200 day moving average of $496.19. Medpace Holdings, Inc. has a one year low of $306.70 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.